TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas

Clinical Endocrinology

Volumn 85, Issue 2, 2016, Pages 283-290

  Bullock, Martyn ^a   Ren, Yan ^b,c,d   O'Neill, Christine ^e   Gill, Anthony ^a,f   Aniss, Adam ^f   Sywak, Mark ^f   Sidhu, Stan ^a,f   Delbridge, Leigh ^f   Learoyd, Diana ^a,f   de Vathaire, Florent ^b,c,d   Robinson, Bruce G ^a,f   Clifton Bligh, Roderick J ^a,f  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b INSERM   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d UNIVERSITÉ PARIS SACLAY   (France)

^e UNIVERSITY OF NEWCASTLE   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; DNA; RADIOACTIVE IODINE; TELOMERASE REVERSE TRANSCRIPTASE;

ADULT; ARTICLE; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENE MUTATION; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; KAPLAN MEIER METHOD; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMOTER REGION; PROPORTIONAL HAZARDS MODEL; REPORTER GENE; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; THYROID CELL; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; TUMOR ABLATION; TUMOR RECURRENCE; TUMOR VOLUME; UNIVARIATE ANALYSIS;

EID: 84978196690     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12999     Document Type: Article

References (28)

1. Kim, N.W., Piatyszek, M.A., Prowse, K.R. et al. (1994) Specific association of human telomerase activity with immortal cells and cancer. Science, 266, 2011–2015.
2. Shay, J.W. & Bacchetti, S. (1997) A survey of telomerase activity in human cancer. European Journal of Cancer, 33, 787–791.
3. Horn, S., Figl, A., Rachakonda, P.S. et al. (2013) TERT promoter mutations in familial and sporadic melanoma. Science, 339, 959–961.
4. Huang, F.W., Hodis, E., Xu, M.J. et al. (2013) Highly recurrent TERT promoter mutations in human melanoma. Science, 339, 957–959.
5. Vinagre, J., Almeida, A., Pópulo, H. et al. (2013) Frequency of TERT promoter mutations in human cancers. Nature Communications, 4, 2185.
6. Fredrikson, N.J., Ny, L., Nilsson, J.A. et al. (2014) Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. Nature Genetics, 46, 1258–1263.
7. Weinhold, N., Jacobsen, A., Schultz, N. et al. (2014) Genome-wide analysis of non-coding regulatory mutations in cancer. Nature Genetics, 46, 1160–1165.
8. Liu, X., Bishop, J., Shan, Y. et al. (2013) Highly prevalent TERT promoter mutations in aggressive thyroid cancer. Endocrine Related Cancer, 20, 603–610.
9. Landa, I., Ganly, I., Chan, T.A. et al. (2013) Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. Journal of Clinical Endocrinology and Metabolism, 98, E1562–E1566.
10. Liu, X., Qu, S., Liu, R. et al. (2014) TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 99, E1130–E1136.
11. Xing, M., Liu, R., Liu, X. et al. (2014) BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. Journal of Clinical Oncology, 32, 2718–2726.
12. Wang, N., Liu, T., Sofiadis, A. et al. (2014) TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. Cancer, 120, 2965–2979.
13. Melo, M., da Rocha, A.G., Vinagre, J. et al. (2014) TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism, 99, E754–E765.
14. George, J.R., Henderson, Y.C., Williams, M.D. et al. (2015) Association of TERT promoter mutation, but not BRAF mutation, with increased mortality in PTC. Journal of Clinical Endocrinology and Metabolism, 100, E1550–E1559.
15. Gandolfi, G., Ragazzi, M., Frasoldati, A. et al. (2015) TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma. European Journal of Endocrinology, 172, 403–413.
16. Muzza, M., Colombo, C., Rossi, S. et al. (2015) Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization. Molecular and Cellular Endocrinology, 399, 288–295.
17. de Biase, D., Gandolfi, G., Ragazzi, M. et al. (2015) TERT promoter mutations in papillary thyroid microcarcinomas. Thyroid, 25, 1013–1019.
18. Chindris, A.M., Casler, J.D., Bernet, V.J. et al. (2015) Clinical and molecular features of Hurthle cell carcinoma of the thyroid. Journal of Clinical Endocrinology and Metabolism, 100, 55–62.
19. Wang, N., Xu, D., Sofiadis, A. et al. (2014) Telomerase-dependent and independent telomere maintenance and its clinical implications in medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 99, E1571–E1579.
20. Nikiforov, Y.E., Carty, S.E., Chiosea, S.I. et al. (2014) Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer, 120, 3627–3634.
21. Liu, R. & Xing, M. (2014) Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy. Endocrine Related Cancer, 21, 825–830.
22. Crescenzi, A., Trimboli, P., Modica, D.C. et al. (2015) Preoperative assessment of TERT promoter mutation on thyroid core needle biopsies supports diagnosis of malignancy and addresses surgical strategy. Hormone and Metabolism Research, [Epub ahead of print].
23. O'Neill, C.J., Bullock, M., Chou, A. et al. (2010) BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery, 148, 1139–1145.
24. Nikiforov, Y.E.B., Paul, W. & Thompson, L.D. (2012) Diagnostic Pathology and Molecular Genetics of the Thyroid: A Comprehensive Guide for Practicing Thyroid Pathology. Baltimore, MD: Lippincott Williams & Wilkins (LWW).
25. Blagosklonny, M.V., Giannakakou, P., Wojtowicz, M. et al. (1998) Effects of p53-expressing adenovirus on the chemosensitivity and differentiation of anaplastic thyroid cancer cells. Journal of Clinical Endocrinology and Metabolism, 83, 2516–2522.
26. Bullock, M., Duncan, E.L., O'Neill, C. et al. (2012) Association of FOXE1 polyalanine repeat region with papillary thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 97, E1814–E1819.
27. Rachakondaa, P.S., Hosena, I., de Verdierb, P.J. et al. (2013) TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proceedings of the National Academy of Sciences of the United States of America, 110, 17426–17431.
28. Lin, J.D., Hsueh, C. & Chao, T.C. (2015) Long-term follow-up of the therapeutic outcomes for papillary thyroid carcinoma with distant metastases. Medicine (Baltimore), 94, e1063.